Nature Reviews Drug Discovery Nature Reviews Drug Discovery integrates academia and industry, providing broad, expert coverage of the whole drug discovery and development arena &ndash; from disease mechanisms, novel therapeutic approaches and chemistry to clinical trials and regulatory affairs. All reviews are carefully commissioned, written by leaders in the field and subject to rigorous peer-review so that readers receive independent, high-quality and authoritative articles in each issue. Reviews are complemented by news stories that investigate the key issues in drug discovery, timely summaries of significant published papers, market analysis, and updates on the latest advances in fast-moving areas such as new technologies, drug approvals and patent law. Information is presented at several levels that can be tailored to users&rsquo; individual needs. Non-specialists will benefit from the glossary and highlighted references, and experts will appreciate the insight provided by top names in their field. Nature Reviews Drug Discovery is a major teaching and reference resource from NPG. http://feeds.nature.com/nrd/rss/current Nature Publishing Group en © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Reviews Drug Discovery © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com Nature Reviews Drug Discovery https://www.nature.com/uploads/product/nrd/rss.gif http://feeds.nature.com/nrd/rss/current <![CDATA[Genome-editing medicinal products: the EMA perspective]]> https://www.nature.com/articles/d41573-024-00050-2 Nature Reviews Drug Discovery, Published online: 15 March 2024; doi:10.1038/d41573-024-00050-2

Genome-editing medicinal products: the EMA perspective]]>
Anna TavridouDolça RogersGiada FarinelliIordanis GravanisVeronika Jekerle doi:10.1038/d41573-024-00050-2 Nature Reviews Drug Discovery, Published online: 2024-03-15; | doi:10.1038/d41573-024-00050-2 2024-03-15 Nature Reviews Drug Discovery 10.1038/d41573-024-00050-2 https://www.nature.com/articles/d41573-024-00050-2
<![CDATA[NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease]]> https://www.nature.com/articles/d41573-024-00051-1 Nature Reviews Drug Discovery, Published online: 14 March 2024; doi:10.1038/d41573-024-00051-1

Madrigal’s resmetirom has scored a landmark FDA win, bolstering hopes for a diverse pipeline of drugs for non-alcoholic steatohepatitis.]]>
Katie Kingwell doi:10.1038/d41573-024-00051-1 Nature Reviews Drug Discovery, Published online: 2024-03-14; | doi:10.1038/d41573-024-00051-1 2024-03-14 Nature Reviews Drug Discovery 10.1038/d41573-024-00051-1 https://www.nature.com/articles/d41573-024-00051-1
<![CDATA[Upcoming market catalysts in Q2 2024]]> https://www.nature.com/articles/d41573-024-00049-9 Nature Reviews Drug Discovery, Published online: 13 March 2024; doi:10.1038/d41573-024-00049-9

Upcoming market catalysts in Q2 2024]]>
Andrew Shui-Jezierski doi:10.1038/d41573-024-00049-9 Nature Reviews Drug Discovery, Published online: 2024-03-13; | doi:10.1038/d41573-024-00049-9 2024-03-13 Nature Reviews Drug Discovery 10.1038/d41573-024-00049-9 https://www.nature.com/articles/d41573-024-00049-9
<![CDATA[Engineered T cells call for back-up]]> https://www.nature.com/articles/d41573-024-00052-0 Nature Reviews Drug Discovery, Published online: 12 March 2024; doi:10.1038/d41573-024-00052-0

Engineered T cells call for back-up]]>
M. Teresa Villanueva doi:10.1038/d41573-024-00052-0 Nature Reviews Drug Discovery, Published online: 2024-03-12; | doi:10.1038/d41573-024-00052-0 2024-03-12 Nature Reviews Drug Discovery 10.1038/d41573-024-00052-0 https://www.nature.com/articles/d41573-024-00052-0
<![CDATA[The European Innovation Network as a hub for medicines innovation in Europe]]> https://www.nature.com/articles/d41573-024-00039-x Nature Reviews Drug Discovery, Published online: 11 March 2024; doi:10.1038/d41573-024-00039-x

The European Innovation Network is working to support the European medical innovation ecosystem by facilitating early dialogue between developers of medicines and regulators, as well as providing a platform for regulators to share information, good practices and expertise.]]>
Eleonora AgricolaCaroline Auriche-BenichouHelena BaiaoOriane BlanquieTeodora BodeaTomáš BoráňJohn-Joseph BorgValentina Cordo’Maria Di MarzoLars Dmowski RugholmFalk EhmannRúna Hauksdóttir HvannbergRalf HeroldAlar IrsSimona Jurkovič MlakarRobert KlausJuha KolehmainenChristophe LahorteWiebke LöbkerAnna Mäkinen SalmiYoana Nuevo OrdoñezLaurence O’DwyerAnna Maria Gerdina PasmooijIngvil SaeterdalBronislava SpakovaViktoriia StarokozhkoBettina ZiegeleKatarzyna Zywiec doi:10.1038/d41573-024-00039-x Nature Reviews Drug Discovery, Published online: 2024-03-11; | doi:10.1038/d41573-024-00039-x 2024-03-11 Nature Reviews Drug Discovery 10.1038/d41573-024-00039-x https://www.nature.com/articles/d41573-024-00039-x
<![CDATA[Shifts in the clinical trial landscape]]> https://www.nature.com/articles/d41573-024-00048-w Nature Reviews Drug Discovery, Published online: 08 March 2024; doi:10.1038/d41573-024-00048-w

Shifts in the clinical trial landscape]]>
Asher Mullard doi:10.1038/d41573-024-00048-w Nature Reviews Drug Discovery, Published online: 2024-03-08; | doi:10.1038/d41573-024-00048-w 2024-03-08 Nature Reviews Drug Discovery 10.1038/d41573-024-00048-w https://www.nature.com/articles/d41573-024-00048-w
<![CDATA[Top companies and drugs by sales in 2023]]> https://www.nature.com/articles/d41573-024-00041-3 Nature Reviews Drug Discovery, Published online: 08 March 2024; doi:10.1038/d41573-024-00041-3

Top companies and drugs by sales in 2023]]>
Paul Verdin doi:10.1038/d41573-024-00041-3 Nature Reviews Drug Discovery, Published online: 2024-03-08; | doi:10.1038/d41573-024-00041-3 2024-03-08 Nature Reviews Drug Discovery 10.1038/d41573-024-00041-3 https://www.nature.com/articles/d41573-024-00041-3
<![CDATA[GSK’s first-in-class antibiotic secures another phase III win, approaches regulatory run]]> https://www.nature.com/articles/d41573-024-00047-x Nature Reviews Drug Discovery, Published online: 08 March 2024; doi:10.1038/d41573-024-00047-x

GSK’s first-in-class antibiotic secures another phase III win, approaches regulatory run]]>
Asher Mullard doi:10.1038/d41573-024-00047-x Nature Reviews Drug Discovery, Published online: 2024-03-08; | doi:10.1038/d41573-024-00047-x 2024-03-08 Nature Reviews Drug Discovery 10.1038/d41573-024-00047-x https://www.nature.com/articles/d41573-024-00047-x